DNLI: חוב כולל להון Denali Therapeutics Inc.

Denali Therapeutics (DNLI) leverages AI and robotics to automate the search for treatments for neuronal degeneration, thereby accelerating preclinical stages. The business model relies on the high margins of patented drugs coupled with global distribution. The debt-to-equity ratio trend on GURU.Markets stands at 0.05. The company's operations are further supported by adherence to environmental standards for chemical disposal and office energy efficiency.

The specific operational model of Denali Therapeutics (DNLI), which delegates the production of neuro-drugs to contractors, minimizes capital expenditures, a factor reflected in its financing structure. The current value of 0.05 is calculated as the ratio of total liabilities to equity, measuring the company's degree of reliance on borrowed funds. An analysis of the financial leverage ratio (total debt-to-equity) determines the resilience of the business model in the face of potential debt risks.